Determination of Regulatory Review Period for Purposes of Patent Extension; CUBICIN, 34375-34376 [E6-9225]
Download as PDF
<![CDATA[
rwilkins on PROD1PC63 with NOTICES
Federal Register / Vol. 71, No. 114 / Wednesday, June 14, 2006 / Notices
417) and the Generic Animal Drug and
Patent Term Restoration Act (Public
Law 100–670) generally provide that a
patent may be extended for a period of
up to 5 years so long as the patented
item (human drug product, animal drug
product, medical device, food additive,
or color additive) was subject to
regulatory review by FDA before the
item was marketed. Under these acts, a
product’s regulatory review period
forms the basis for determining the
amount of extension an applicant may
receive.
A regulatory review period consists of
two periods of time: A testing phase and
an approval phase. For human drug
products, the testing phase begins when
the exemption to permit the clinical
investigations of the human drug
product becomes effective and runs
until the approval phase begins. The
approval phase starts with the initial
submission of an application to market
the human drug product and continues
until FDA grants permission to market
the drug product. Although only a
portion of a regulatory review period
may count toward the actual amount of
extension that the Director of Patents
and Trademarks may award (for
example, half the testing phase must be
subtracted as well as any time that may
have occurred before the patent was
issued), FDA’s determination of the
length of a regulatory review period for
a human drug product will include all
of the testing phase and approval phase
as specified in 35 U.S.C. 156(g)(1)(B).
FDA recently approved for marketing
the human drug product DUTASTERIDE
(dutasteride). DUTASTERIDE is
indicated for the treatment of
symptomatic benign prostatic
hyperplasia in men with an enlarged
prostate gland. Subsequent to this
approval, the Patent and Trademark
Office received a patent term restoration
application for DUTASTERIDE (U.S.
Patent No. 5,565,467) from
GlaxoSmithKline, and the Patent and
Trademark Office requested FDA’s
assistance in determining this patent’s
eligibility for patent term restoration. In
a letter dated October 31, 2002, FDA
advised the Patent and Trademark
Office that this human drug product had
undergone a regulatory review period
and that the approval of DUTASTERIDE
represented the first permitted
commercial marketing or use of the
product. Shortly thereafter, the Patent
and Trademark Office requested that
FDA determine the product’s regulatory
review period.
FDA has determined that the
applicable regulatory review period for
DUTASTERIDE is 2,373 days. Of this
time, 2,038 days occurred during the
VerDate Aug<31>2005
19:47 Jun 13, 2006
Jkt 208001
testing phase of the regulatory review
period, while 335 days occurred during
the approval phase. These periods of
time were derived from the following
dates:
1. The date an exemption under
section 505(i) of the Federal Food, Drug,
and Cosmetic Act (the act) (21 U.S.C.
355(i)) became effective: May 25, 1995.
The applicant claims April 24, 1995, as
the date the investigational new drug
application (IND) became effective.
However, FDA records indicate that the
IND effective date was May 25, 1995,
which was 30 days after FDA receipt of
the IND.
2. The date the application was
initially submitted with respect to the
human drug product under section
505(b) of the act: December 21, 2000.
FDA has verified the applicant’s claim
that the new drug application (NDA) for
DUTASTERIDE (NDA 21–319) was
initially submitted on December 21,
2000.
3. The date the application was
approved: November 20, 2001. FDA has
verified the applicant’s claim that NDA
21–319 was approved on November 20,
2001.
This determination of the regulatory
review period establishes the maximum
potential length of a patent extension.
However, the U.S. Patent and
Trademark Office applies several
statutory limitations in its calculations
of the actual period for patent extension.
In its application for patent extension,
this applicant seeks 769 days of patent
term extension.
Anyone with knowledge that any of
the dates as published are incorrect may
submit to the Division of Dockets
Management (see ADDRESSES) written or
electronic comments and ask for a
redetermination by August 14, 2006.
Furthermore, any interested person may
petition FDA for a determination
regarding whether the applicant for
extension acted with due diligence
during the regulatory review period by
December 11, 2006. To meet its burden,
the petition must contain sufficient facts
to merit an FDA investigation. (See H.
Rept. 857, part 1, 98th Cong., 2d sess.,
pp. 41–42, 1984.) Petitions should be in
the format specified in 21 CFR 10.30.
Comments and petitions should be
submitted to the Division of Dockets
Management. Three copies of any
mailed information are to be submitted,
except that individuals may submit one
copy. Comments are to be identified
with the docket number found in
brackets in the heading of this
document. Comments and petitions may
be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
34375
Dated: May 17, 2006.
Jane A. Axelrad,
Associate Director for Policy, Center for Drug
Evaluation and Research.
[FR Doc. E6–9224 Filed 6–13–06; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2006E–0042]
Determination of Regulatory Review
Period for Purposes of Patent
Extension; CUBICIN
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) has determined
the regulatory review period for
CUBICIN and is publishing this notice
of that determination as required by
law. FDA has made the determination
because of the submission of an
application to the Director of Patents
and Trademarks, Department of
Commerce, for the extension of a patent
that claims that human drug product.
ADDRESSES: Submit written comments
and petitions to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.fda.gov/dockets/ecomments.
FOR FURTHER INFORMATION CONTACT:
Beverly Friedman, Office of Regulatory
Policy (HFD–7), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–594–2041.
SUPPLEMENTARY INFORMATION: The Drug
Price Competition and Patent Term
Restoration Act of 1984 (Public Law 98–
417) and the Generic Animal Drug and
Patent Term Restoration Act (Public
Law 100–670) generally provide that a
patent may be extended for a period of
up to 5 years so long as the patented
item (human drug product, animal drug
product, medical device, food additive,
or color additive) was subject to
regulatory review by FDA before the
item was marketed. Under these acts, a
product’s regulatory review period
forms the basis for determining the
amount of extension an applicant may
receive.
A regulatory review period consists of
two periods of time: A testing phase and
an approval phase. For human drug
products, the testing phase begins when
the exemption to permit the clinical
investigations of the drug becomes
E:\FR\FM\14JNN1.SGM
14JNN1
rwilkins on PROD1PC63 with NOTICES
34376
Federal Register / Vol. 71, No. 114 / Wednesday, June 14, 2006 / Notices
effective and runs until the approval
phase begins. The approval phase starts
with the initial submission of an
application to market the human drug
product and continues until FDA grants
permission to market the drug product.
Although only a portion of a regulatory
review period may count toward the
actual amount of extension that the
Director of Patents and Trademarks may
award (for example, half the testing
phase must be subtracted as well as any
time that may have occurred before the
patent was issued), FDA’s determination
of the length of a regulatory review
period for a human drug product will
include all of the testing phase and
approval phase as specified in 35 U.S.C.
156(g)(1)(B).
FDA recently approved for marketing
the human drug product CUBICIN
(daptomycin). CUBICIN is indicated for
the treatment of complicated skin and
skin structure infections caused by
susceptible strains of the following
Gram-positive microorganisms:
Staphylococcus aureus (including
methicillin-resistant strains),
Streptococcus pyogenes, S. agalactiae,
S. dysgalactiae subsp. equismilis, and
Enterococcus faecalis (vancomycinsusceptible strains only). Subsequent to
this approval, the Patent and Trademark
Office received a patent term restoration
application for CUBICIN (U.S. Patent
No. 4,885,243) from Cubist
Pharmaceuticals, Inc., and the Patent
and Trademark Office requested FDA’s
assistance in determining this patent’s
eligibility for patent term restoration. In
a letter dated February 24, 2006, FDA
advised the Patent and Trademark
Office that this human drug product had
undergone a regulatory review period
and that the approval of CUBICIN
represented the first permitted
commercial marketing or use of the
product. Shortly thereafter, the Patent
and Trademark Office requested that
FDA determine the product’s regulatory
review period.
FDA has determined that the
applicable regulatory review period for
CUBICIN is 6,444 days. Of this time,
6,177 days occurred during the testing
phase of the regulatory review period,
while 267 days occurred during the
approval phase. These periods of time
were derived from the following dates:
1. The date an exemption under
section 505(i) of the Federal Food, Drug,
and Cosmetic Act (the act) (21 U.S.C.
355(i)) became effective: January 22,
1986. The applicant claims January 18,
1986, as the date the investigational new
drug application (IND) became effective.
However, FDA records indicate that the
IND effective date was January 22, 1986,
VerDate Aug<31>2005
19:47 Jun 13, 2006
Jkt 208001
which was 30 days after FDA receipt of
the IND.
2. The date the application was
initially submitted with respect to the
human drug product under section
505(b) of the act: December 20, 2002.
FDA has verified the applicant’s claim
that the new drug application (NDA) for
CUBICIN (NDA 21–572) was initially
submitted on December 20, 2002.
3. The date the application was
approved: September 12, 2003. FDA has
verified the applicant’s claim that NDA
21–572 was approved on September 12,
2003.
This determination of the regulatory
review period establishes the maximum
potential length of a patent extension.
However, the U.S. Patent and
Trademark Office applies several
statutory limitations in its calculations
of the actual period for patent extension.
In its application for patent extension,
this applicant seeks 1,347 days of patent
term extension.
Anyone with knowledge that any of
the dates as published are incorrect may
submit to the Division of Dockets
Management (see ADDRESSES) written or
electronic comments and ask for a
redetermination by August 14, 2006.
Furthermore, any interested person may
petition FDA for a determination
regarding whether the applicant for
extension acted with due diligence
during the regulatory review period by
December 11, 2006. To meet its burden,
the petition must contain sufficient facts
to merit an FDA investigation. (See H.
Rept. 857, part 1, 98th Cong., 2d sess.,
pp. 41–42, 1984.) Petitions should be in
the format specified in 21 CFR 10.30.
Comments and petitions should be
submitted to the Division of Dockets
Management. Three copies of any
mailed information are to be submitted,
except that individuals may submit one
copy. Comments are to be identified
with the docket number found in
brackets in the heading of this
document. Comments and petitions may
be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
Dated: May 17, 2006.
Jane A. Axelrad,
Associate Director for Policy, Center for Drug
Evaluation and Research.
[FR Doc. E6–9225 Filed 6–13–06; 8:45 am]
BILLING CODE 4160–01–S
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Cooperative
Research and Development Agreement
(CRADA) Opportunity for Furthering
the Development of a Suite of
Computer Programs for Modeling and
Simulating Complex Cellular Biological
Processes
ACTION:
Notice.
SUMMARY: The National Institute of
Allergy and Infectious Diseases (NIAID),
a component of the National Institutes
of Health (NIH), Department of Health
and Human Services (HHS), seeks to
enter into a CRADA with a commercial
partner to co-develop a suite of
computer programs for modeling and
simulating complex cellular biological
processes.
The existing suite of computer
programs allows biologists to develop
and test quantitative models of cell
biological processes. The graphical
interfaces of the programs make it
possible to develop realistic models of
molecular interactions and cellular
processes that take into account the
intracellular and extracellular spatial
inhomogeneity of signaling components
without the user having to deal with the
partial differential equations and state
automata that underlie the quantitative
simulation of the models. The program
suite offers graphical symbols and dragand-drop mechanisms to define
molecular interactions, molecular
complexes, cellular stimulus-response
mechanisms, and the structure of
extracellular compartments. An
intuitive graphical interface can be used
to inspect and interact with running
simulations; for example, molecules and
cells can be placed into the simulated
compartments, cells can be selected for
detailed analysis of their behavior and
intracellular, spatially-resolved
biochemistry. One part of the program
suite reads the molecular interaction
network data that are generated by the
program based on the user defined
bimolecular interactions and displays
them as interaction graphs, visualizing
the reaction dynamics in the modeled
cellular signaling pathways.
It is anticipated that the collaboration
will result in the commercialization of
the software.
DATES: NIAID will consider all
capability statements received within 45
days of the date of publication of this
notice. Capability statements received
thereafter may be considered if a
E:\FR\FM\14JNN1.SGM
14JNN1
]]>Agencies
[Federal Register Volume 71, Number 114 (Wednesday, June 14, 2006)]
[Notices]
[Pages 34375-34376]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-9225]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2006E-0042]
Determination of Regulatory Review Period for Purposes of Patent
Extension; CUBICIN
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) has determined the
regulatory review period for CUBICIN and is publishing this notice of
that determination as required by law. FDA has made the determination
because of the submission of an application to the Director of Patents
and Trademarks, Department of Commerce, for the extension of a patent
that claims that human drug product.
ADDRESSES: Submit written comments and petitions to the Division of
Dockets Management (HFA-305), Food and Drug Administration, 5630
Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments
to https://www.fda.gov/dockets/ecomments.
FOR FURTHER INFORMATION CONTACT: Beverly Friedman, Office of Regulatory
Policy (HFD-7), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-594-2041.
SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term
Restoration Act of 1984 (Public Law 98-417) and the Generic Animal Drug
and Patent Term Restoration Act (Public Law 100-670) generally provide
that a patent may be extended for a period of up to 5 years so long as
the patented item (human drug product, animal drug product, medical
device, food additive, or color additive) was subject to regulatory
review by FDA before the item was marketed. Under these acts, a
product's regulatory review period forms the basis for determining the
amount of extension an applicant may receive.
A regulatory review period consists of two periods of time: A
testing phase and an approval phase. For human drug products, the
testing phase begins when the exemption to permit the clinical
investigations of the drug becomes
[[Page 34376]]
effective and runs until the approval phase begins. The approval phase
starts with the initial submission of an application to market the
human drug product and continues until FDA grants permission to market
the drug product. Although only a portion of a regulatory review period
may count toward the actual amount of extension that the Director of
Patents and Trademarks may award (for example, half the testing phase
must be subtracted as well as any time that may have occurred before
the patent was issued), FDA's determination of the length of a
regulatory review period for a human drug product will include all of
the testing phase and approval phase as specified in 35 U.S.C.
156(g)(1)(B).
FDA recently approved for marketing the human drug product CUBICIN
(daptomycin). CUBICIN is indicated for the treatment of complicated
skin and skin structure infections caused by susceptible strains of the
following Gram-positive microorganisms: Staphylococcus aureus
(including methicillin-resistant strains), Streptococcus pyogenes, S.
agalactiae, S. dysgalactiae subsp. equismilis, and Enterococcus
faecalis (vancomycin-susceptible strains only). Subsequent to this
approval, the Patent and Trademark Office received a patent term
restoration application for CUBICIN (U.S. Patent No. 4,885,243) from
Cubist Pharmaceuticals, Inc., and the Patent and Trademark Office
requested FDA's assistance in determining this patent's eligibility for
patent term restoration. In a letter dated February 24, 2006, FDA
advised the Patent and Trademark Office that this human drug product
had undergone a regulatory review period and that the approval of
CUBICIN represented the first permitted commercial marketing or use of
the product. Shortly thereafter, the Patent and Trademark Office
requested that FDA determine the product's regulatory review period.
FDA has determined that the applicable regulatory review period for
CUBICIN is 6,444 days. Of this time, 6,177 days occurred during the
testing phase of the regulatory review period, while 267 days occurred
during the approval phase. These periods of time were derived from the
following dates:
1. The date an exemption under section 505(i) of the Federal Food,
Drug, and Cosmetic Act (the act) (21 U.S.C. 355(i)) became effective:
January 22, 1986. The applicant claims January 18, 1986, as the date
the investigational new drug application (IND) became effective.
However, FDA records indicate that the IND effective date was January
22, 1986, which was 30 days after FDA receipt of the IND.
2. The date the application was initially submitted with respect to
the human drug product under section 505(b) of the act: December 20,
2002. FDA has verified the applicant's claim that the new drug
application (NDA) for CUBICIN (NDA 21-572) was initially submitted on
December 20, 2002.
3. The date the application was approved: September 12, 2003. FDA
has verified the applicant's claim that NDA 21-572 was approved on
September 12, 2003.
This determination of the regulatory review period establishes the
maximum potential length of a patent extension. However, the U.S.
Patent and Trademark Office applies several statutory limitations in
its calculations of the actual period for patent extension. In its
application for patent extension, this applicant seeks 1,347 days of
patent term extension.
Anyone with knowledge that any of the dates as published are
incorrect may submit to the Division of Dockets Management (see
ADDRESSES) written or electronic comments and ask for a redetermination
by August 14, 2006. Furthermore, any interested person may petition FDA
for a determination regarding whether the applicant for extension acted
with due diligence during the regulatory review period by December 11,
2006. To meet its burden, the petition must contain sufficient facts to
merit an FDA investigation. (See H. Rept. 857, part 1, 98th Cong., 2d
sess., pp. 41-42, 1984.) Petitions should be in the format specified in
21 CFR 10.30.
Comments and petitions should be submitted to the Division of
Dockets Management. Three copies of any mailed information are to be
submitted, except that individuals may submit one copy. Comments are to
be identified with the docket number found in brackets in the heading
of this document. Comments and petitions may be seen in the Division of
Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.
Dated: May 17, 2006.
Jane A. Axelrad,
Associate Director for Policy, Center for Drug Evaluation and Research.
[FR Doc. E6-9225 Filed 6-13-06; 8:45 am]
BILLING CODE 4160-01-S
